Drug General Information
Drug ID
D0K5CJ
Former ID
DIB007914
Drug Name
DAVLB-HYDRAZIDE
Synonyms
Desacetylvinblastine-3-carboxyhydrazide; 3aalpha-Ethyl-9-[5alpha-ethyl-5beta-hydroxy-9beta-(methoxycarbonyl)-1,2,4,5,6,7beta,8,9-octahydro-10H-3,7-methanoazacycloundecino[5,4-b]indol-9alpha-yl)-4beta,5beta-dihydroxy-8-methoxy-6-methyl-3a,4,5
Drug Type
Small molecular drug
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 1 [530726]
Structure
Download
2D MOL

3D MOL

Formula
C14H14N2O4
Canonical SMILES
CC(=O)CCC1C(=O)NC(=O)N(C1=O)C2=CC=CC=C2
InChI
1S/C14H14N2O4/c1-9(17)7-8-11-12(18)15-14(20)16(13(11)19)10-5-3-2-4-6-10/h2-6,11H,7-8H2,1H3,(H,15,18,20)
InChIKey
WTMIEMJOWOUDNF-UHFFFAOYSA-N
CAS Number
CAS 55383-37-4
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Tubulin beta Target Info Modulator [544311], [551871]
KEGG Pathway Phagosome
Gap junction
Pathogenic Escherichia coli infection
NetPath Pathway FSH Signaling Pathway
TCR Signaling Pathway
EGFR1 Signaling Pathway
PANTHER Pathway Cytoskeletal regulation by Rho GTPase
Huntington disease
Reactome Regulation of PLK1 Activity at G2/M Transition
Loss of Nlp from mitotic centrosomes
Recruitment of mitotic centrosome proteins and complexes
Loss of proteins required for interphase microtubule organization?from the centrosome
Anchoring of the basal body to the plasma membrane
WikiPathways Parkin-Ubiquitin Proteasomal System pathway
Pathogenic Escherichia coli infection
Mitotic G2-G2/M phases
References
Ref 530726The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies. Cancer Res. 1991 May 1;51(9):2286-90.
Ref 544311An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site. Pharm Res. 2012 November; 29(11): 2943-2971.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.